NYSE:WAT - Waters Stock Price, News, & Analysis

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters declared that its board has initiated a stock buyback program on Tuesday, April 24th 2018, which allows the company to repurchase $3,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy up to 18.2% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company's board believes its stock is undervalued.

Waters Co. (NYSE:WAT) posted its quarterly earnings data on Wednesday, January, 23rd. The medical instruments supplier reported $2.87 EPS for the quarter, beating the consensus estimate of $2.64 by $0.23. The medical instruments supplier had revenue of $715 million for the quarter, compared to analyst estimates of $702.74 million. Waters had a net margin of 24.54% and a return on equity of 34.18%. Waters's revenue for the quarter was up 4.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.51 earnings per share. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, April 23rd 2019. View Earnings Estimates for Waters.

Waters issued an update on its FY19 earnings guidance on Wednesday, January, 23rd. The company provided earnings per share (EPS) guidance of $9.20-9.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.18. Waters also updated its FY 2019 guidance to $9.20-9.45 EPS.

14 equities research analysts have issued 12-month price targets for Waters' stock. Their predictions range from $177.00 to $260.00. On average, they expect Waters' share price to reach $205.3715 in the next twelve months. This suggests that the stock has a possible downside of 17.4%. View Analyst Price Targets for Waters.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 2 sell ratings, 11 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Waters.

Media stories about WAT stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Waters earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future.

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), PerkinElmer (PKI), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Pacific Biosciences of California (PACB), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Quanterix (QTRX), Eyepoint Pharmaceuticals (EYPT) and Harvard Bioscience (HBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Waters investors own include Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Home Depot (HD), Cisco Systems (CSCO), Walmart (WMT), Raytheon (RTN), Mcdonald's (MCD), Honeywell International (HON), Northrop Grumman (NOC) and Visa (V).

Waters' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.36%), Fundsmith LLP (6.51%), Massachusetts Financial Services Co. MA (6.42%), Bank of New York Mellon Corp (5.83%), Baillie Gifford & Co. (3.32%) and Jensen Investment Management Inc. (1.39%). Company insiders that own Waters stock include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Robert G Carson, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including Nomura Asset Management Co. Ltd., Ownership Capital B.V., Bank of New York Mellon Corp, D. E. Shaw & Co. Inc., FMR LLC, Fundsmith LLP, Bessemer Group Inc. and Mackenzie Financial Corp. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, Elizabeth B Rae, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Robert G Carson, Terrence P Kelly and Thomas P Salice. View Insider Buying and Selling for Waters.

WAT stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Bristol John W & Co. Inc. NY, Massachusetts Financial Services Co. MA, American Century Companies Inc., Nordea Investment Management AB, Citigroup Inc., Geode Capital Management LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $248.77.

Waters has a market capitalization of $17.79 billion and generates $2.42 billion in revenue each year. The medical instruments supplier earns $593.79 million in net income (profit) each year or $8.29 on an earnings per share basis. Waters employs 7,200 workers across the globe.

The official website for Waters is http://www.waters.com.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]